Usefulness of compounds with monacolin K in a case of statins intolerance

Clin Investig Arterioscler. 2018 Nov-Dec;30(6):268-270. doi: 10.1016/j.arteri.2018.06.003. Epub 2018 Oct 9.
[Article in English, Spanish]


Many patients with familial hypercholesterolaemia (FH) or in secondary prevention situations and with statin intolerance do not achieve LDL-C targets, and require treatment with PCSK9 inhibitors (iPCSK9) and ezetimibe. The case is presented on a patient with FH and total intolerance to statins. Treatment with iPCSK9 and ezetimibe failed to achieve her LDL-C target. A compound with red yeast rice derivatives containing 3mg of monacolin K was added, with good therapeutic compliance, and a very good control of LDL-C. The addition of red yeast rice derivatives containing low doses of monacolin K, together with IPCSK9 in patients with total intolerance to statins, may open a new path to obtain LDL-C targets in patients with high/very high cardiovascular risk.

Keywords: Inhibidores de PCSK9; Intolerancia a las estatinas; Monacolin K; Monacolina K; PCSK9 inhibitors; Statins intolerance.

Publication types

  • Case Reports

MeSH terms

  • Anticholesteremic Agents / administration & dosage*
  • Biological Products / administration & dosage
  • Cholesterol, LDL / blood
  • Drug Therapy, Combination
  • Ezetimibe / administration & dosage*
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
  • Hyperlipoproteinemia Type II / drug therapy*
  • Lovastatin / administration & dosage*
  • Middle Aged
  • PCSK9 Inhibitors


  • Anticholesteremic Agents
  • Biological Products
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • PCSK9 Inhibitors
  • red yeast rice
  • Lovastatin
  • PCSK9 protein, human
  • Ezetimibe